Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-02-21
2006-02-21
Rao, Deepak (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S237800, C514S255010, C514S329000, C514S335000, C514S352000, C514S357000, C514S406000, C514S415000, C514S423000, C514S424000, C514S452000, C548S200000, C548S338100, C548S362100, C548S371700, C548S506000, C548S539000, C548S550000, C548S568000, C546S208000, C546S224000, C546S242000, C546S226000, C546S309000, C544S059000, C544S169000, C562S456000, C562S457000, C562S622000, C562S623000
Reexamination Certificate
active
07001905
ABSTRACT:
Diarylamines, such as 5-amide substituted diarylamines of formula (I) or formula (II) wherein A is hydroxy, C1-6alkoxy, or NR6OR7; X is OR12, NR13R12, or NR14; inhibitors of MEK and are useful in the treatment of a variety of proliferative disease states, such as conditions related to the hyperactivity of MEK, as well as diseases modulated by the MEK cascade.
REFERENCES:
patent: 5068250 (1991-11-01), Penning et al.
patent: 5525625 (1996-06-01), Bridges et al.
patent: 6310060 (2001-10-01), Barrett et al.
patent: WO 93/24442 (1993-12-01), None
patent: WO 95/22992 (1995-08-01), None
patent: WO 97/07790 (1997-03-01), None
patent: WO 98/37881 (1998-09-01), None
patent: WO 99/01421 (1999-01-01), None
patent: WO 99/01426 (1999-01-01), None
patent: WO 00/41994 (2000-07-01), None
patent: WO 00/42002 (2000-07-01), None
patent: WO 00/42003 (2000-07-01), None
patent: WO 00/42022 (2000-07-01), None
patent: WO 00/42029 (2000-07-01), None
Traxler, Protein Tyrosine Kinase inhibitors in cancer treatment, Exp. Opin. Ther. Patents, 7(6): 571-588, 1997.
Simone, Oncology: Introduction, Cecil Textbook of Medicine, 20thEdition, vol. 1, pp. 1004-1010, 1996.
Lonn et al., Drug treatment in heart failure, BMJ, vol. 320, pp. 1188-1192, Apr. 2000.
Brigden, MD, M. L., “A Practical Workup for Eosinophilia,”Postgraduate Medicine1999, 193-210, vol. 105, No. 3.
Duesbery, N., et al., “MEK Wars, A New Front in the Battle Against Cancer,”Nature Medicine, 1999, 736-737, vol. 5, No. 7.
Duncia, J. V., et al., “MEK Inhibitors: The Chemistry and Bilogical Activity of U0126, its Analogs, and Cyclization Products,”Bioorganic & Medicinal Chemistry Letters, 1998, 2839-2844, vol.8.
Ji, R., et al., “Nociceptive-Specific Activation of ERK in Spinal Neurons Contributes to Pain Hypersensitivity,”Nature Neuroscience, 1999, 1114-1119, vol. 2, No. 12.
Sebolt-Leopold, J. S., et al., “Blockade of the MAP Kinase Pathway Suppresses Growth of Colon Tumors in vivo,”Nature Medicine, 1999, 810-816, vol. 5, No. 7.
Sebolt-Leopold, J. S., “Development of Anticancer Drugs Targeting the MAP Kinase Pathway,”Oncogene, 2000, 6594-6599, vol. 19.
Biwersi Cathlin
Tecle Haile
Warmus Joseph Scott
Rao Deepak
Warner-Lambert & Company
Yakovleva Galina M.
Zielinski Bryan C.
LandOfFree
Substituted diarylamines as MEK inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted diarylamines as MEK inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted diarylamines as MEK inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3629214